GlassScriptPhysician profile
Hannah Amanda Johnson
NPI 1881295269
$26,569.35
in general payments reported to CMS, 2019-2025
33 companies · $6,400 in 2025
The $6,400 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,888 · 2022: $4,237 · 2023: $5,929 · 2024: $7,115 · 2025: $6,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Education: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,631.76 |
| Education | $812.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,771.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,204.17 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,163.77 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $2,058.68 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Janssen Biotech, INC. | $1,823.01 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $1,724.18 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,695.46 | 2021-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $1,694.37 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Pfizer INC. | $1,305.62 | 2021-2025 | |
| Lilly USA, LLC | $1,093.79 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $979.73 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $960.86 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $919.13 | 2023-2024 | Vtama |
| Incyte Corporation | $828.02 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $723.88 | 2021-2025 | Adbry, Anzupgo, Spevigo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $491.42 | 2021-2025 | Seysara, Klisyri |
| Organon LLC | $466.40 | 2024-2025 | Vtama, Nexplanon |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $391.08 | 2021-2025 | Cabtreo, Arazlo, Siliq |
| Journey Medical Corporation | $233.78 | 2022 | |
| Sanofi-Aventis U.S. LLC | $172.99 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.53 | 2023-2025 | Spevigo, Cyltezo |
| Amgen INC. | $154.68 | 2021-2024 | Otezla |
| Mayne Pharma Commercial LLC | $119.86 | 2021-2022 | |
| Epi Health, LLC | $109.30 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $98.71 | 2021 | |
| Strata Skin Sciences, INC. | $37.91 | 2025 | Xtrac |
| Nabriva Therapeutics, Plc | $36.75 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $32.22 | 2024 | Idacio |
| Verrica Pharmaceuticals INC. | $28.66 | 2023 | Ycanth |
| Botanix Sb INC | $21.63 | 2025 | Sofdra |
| Biofrontera INC. | $21.31 | 2025 | |
| Paratek Pharmaceuticals, INC. | $21.11 | 2022 | |
| Sebela Pharmaceuticals INC. | $14.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.